Immix Biopharma (IMMX) investor relations material

Disease background and unmet need

• Approximately 38,500 U.S. patients suffer from relapsed/refractory AL amyloidosis, with no FDA-approved therapies available for this population.

• Current standards of care yield only a 0-10% complete response rate, leaving most patients with poor outcomes and limited options.

• AL amyloidosis is caused by rogue plasma cells producing toxic light chains that damage organs, leading to heart, kidney, and liver failure.

• Most patients relapse after frontline therapy, and off-label drug use is common but largely ineffective.

NXC-201 therapy and clinical platform

• NXC-201 is a sterically-optimized CAR-T therapy targeting BCMA on plasma cells, aiming to eliminate the source of toxic light chains.

• The therapy incorporates proprietary modifications to reduce non-specific activation, cytokine release, and neurotoxicity, while enhancing cytotoxicity and expansion.

• NXC-201 is designed as a single-infusion, one-and-done therapy, contrasting with multi-dose regimens of other agents.

Clinical trial results and efficacy

• In the NEXICART-2 U.S. phase 1/2 trial, NXC-201 achieved a 95% complete response rate in relapsed/refractory AL amyloidosis patients as of May 2026.

• Rapid normalization of disease markers and 100% organ response in evaluable patients were observed.

• The complete response rate improved from 75% in December 2025 to 95% in May 2026.

• NXC-201 outperformed other BCMA-targeted therapies in both depth and speed of response, even in heavily pretreated populations.